INTRODUCTION
Pain control in clinical dentistry is mainly achieved using local anaesthetic (LA) drugs. Articaine was originally synthesised as carticaine in 1969 and entered clinical practice in Germany in 1976. 1 The name was changed in 1984, the year it was released in Canada. 2 It then entered the United Kingdom in 1998, 1 the United States in 2000 3 and Australia in 2005. 4 Currently, articaine is available as a 4% solution containing 1:100, 000 or 1:200, 000 adrenaline.
PHARMACOLOGY
Articaine (4-methyl-3-[2-(propylamino)-propionamido]-2-thiophene-carboxylic acid, methyl ester hydrochloride) is a unique amide LA in that it contains a thiophene, instead of a benzene, ring (Fig. 1) . The thiophene ring allows greater lipid solubility and potency as a greater portion of an administered dose can enter neurons. 5 It is the only amide anaesthetic containing an ester group, allowing hydrolysation in unspecific blood esterases. 6 Articaine is one of the most recent local anaesthetic drugs made available to dentists worldwide. Anecdotal reports advocate its superiority over other common local anaesthetic agents and controversy exists concerning its clinical safety. This article reviews the current literature on articaine use in dentistry specifically addressing the issues of efficacy and safety.
serum half-life of articaine is 20 minutes 6 and of articainic acid is 64 minutes. 7 Equal analgesic efficacy and a lower systemic toxicity (a wide therapeutic range) allows articaine use in a concentration higher than other amide LAs. 6 Following maxillary tooth extractions, a high articaine concentration in alveolus blood has been shown post extraction, with an increasing metabolic ratio of articaine to articanic acid. 9 It is believed that local saturation of serum esterases, causing slower and prolonged metabolism, may contribute neurotoxicity and highlights the quality of the available evidence. 
I N B R I E F GENERAL

GENERAL
to the advantageous relationship between persistence of the local anaesthetic effect and low systemic toxicity. 10 The increased duration of the local anaesthetic effect may also be related to the high degree of protein binding, where the increased tendency for articaine to attach securely to the protein receptor site may provide a longer duration of clinical activity.
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There is no correlation between the serum concentration and local anaesthetic effect of articaine.
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EFFICACY
Articaine can provide clinically effective pain relief for most dental procedures similar to other commercially available local anaesthetics 1 and has also been reported to provide sufficient anaesthesia for reduction of complex orbitozygomatic fractures under local anaesthesia. 12 Anaesthetic concentration has no significant effect on clinical efficacy. When 2% and 4% articaine with 1:200,000 adrenaline (2% A200 and 4% A200 respectively) were used for extractions of maxillary and mandibular teeth, 4% A200 did not have a superior anaesthetic effect. 13, 14 However an in vitro study showed that 2% and 4% articaine more effectively depressed the compound action potential of all A fibres in rat sensory nerves than 2% and 4% lignocaine and 3% mepivacaine could and 4% articaine was more effective than 2% articaine. 15 Currently it is not known why articaine is only manufactured in a 4% solution given that the limited data show no clinical advantage over a 2% preparation. One reason may be that the lower systemic toxicity of articaine allows it to be used in a concentration higher than other amide LAs. 6 Vasoconstrictor concentration has had little effect on certain clinical properties. In mandibular first premolars anaesthetised with an inferior alveolar nerve block (IANB), no significant differences in the duration of or ability to induce pulp and soft tissue anaesthesia, as determined by electric pulp tester (EPT) readings or patient reported lip numbness, were observed between 4% articaine with 1:100,000 adrenaline (4% A100) and 4% A200. 16 Similarly, no significant differences were found in the level of pulpal anaesthesia between 4% A100 and 4% A200 for maxillary infiltration and IANB anaesthesia. 17 Hersh et al.
found that plasma concentration curves were similar in patients receiving both 4% A100 and 4% A200 and concluded that 4% A200 is as safe as 4% A100. 18 For patients receiving 4% A200 and 2% lignocaine with 1:100,000 adrenaline (2% L100), no significant difference was found between the two solutions in regard to heart rate, systolic and diastolic blood pressure and oxygen saturation. 19 In the surgical setting, adrenaline concentration in 4% A100 or 4% A200 has been shown not to affect the patient's perception of anaesthetic duration, postoperative analgesia or clinical efficacy during the removal of mandibular third molars. 20 When extracting impacted maxillary third molars, a higher buccal vestibule-palatal diffusion occurred with a greater concentration of adrenaline (4% A100 compared to 4% A200) after ten minutes. 21 In periodontal surgery, both 4% A100 and 4% A200 provided similar levels of patient-reported pain control, however, 4% A100 provided less bleeding and better visualisation of the surgical field.
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COMPARISON WITH OTHER ANAESTHETICS
Clinical trials comparing articaine with other LAs have varied in study design and site of action with most comparisons made with lignocaine, the current standard to which all new local anaesthetics are compared. 2 Anaesthetic success of sound teeth in healthy volunteers has been defined as the ability to achieve two or more consecutive EPT readings of 80. An early report by Cowan revealed that while carticaine had satisfactory clinical properties, it also had a variable onset time and poor predictability for profound anaesthesia. 23 Anaesthesia of maxillary teeth have had varying results; articaine has been shown to have a significantly shorter latency and longer duration of pulpal anaesthesia than lignocaine in posterior teeth 24 but not in anterior teeth. 25, 26 Articaine also has a significantly higher success rate than lignocaine in the maxillary lateral incisor but not in the maxillary first molar. 27 No significant differences between prilocaine and articaine were found in onset time and anaesthetic duration 28 or in the ability of the two LAs to induce pulpal, buccal or palatal tissue anaesthesia in maxillary canines 29 or second molars. 30 Trials comparing mandibular buccal infiltrations have found no significant difference in anaesthetic success rate for pulpal, buccal or lingual tissue for mandibular canines 29 or mandibular second molars 30 when articaine and prilocaine were used, or when buccal infiltrations were compared to buccal and lingual infiltrations of articaine in mandibular first molars. 31 Alternatively, articaine buccal infiltrations have had significantly higher anaesthetic success rates than lignocaine in mandibular first molars, 32,33 mandibular premolars and molars 34 and in the incisive/mental nerve block for mandibular premolars, canines and lateral incisors. 35 No significant differences in their ability to achieve pulpal anaesthesia were found between articaine and lignocaine when a periodontal ligament (PDL) infiltration was used in mandibular first molars. 36 The inferior alveolar nerve block (IANB) is commonly used for employing pulpal anaesthesia of mandibular teeth however its success has been relatively modest, with approximately 15 to 20% of IANBs providing inadequate anaesthesia. 2 Articaine and lignocaine had similar success rates when used for administering the IANB. 37 A supplemental buccal infiltration of articaine adjacent to a mandibular molar after an IANB has been shown to have a significantly higher success rate than lignocaine or a dummy injection in mandibular posterior 38 and anterior teeth. 39 Other reports show no significant increase in anaesthetic success of mandibular teeth when lignocaine is used as a supplemental buccal or lingual infiltration 40 or mylohyoid nerve block after an IANB. 41 When articaine was used for either an IANB or buccal infiltration, both techniques had similar success rates in providing mandibular first molar pulpal anaesthesia however a buccal infiltration had a faster latency. 42 After surgical extraction of impacted mandibular third molars, articaine had a longer duration of postoperative anaesthesia and a significantly longer analgesic duration than mepivacaine 43 and lignocaine. 44 Articaine also had a significantly shorter latency and duration of soft tissue anaesthesia than bupivacaine but a similar duration of postoperative analgesia. 45 For maxillary tooth extractions, it has been suggested that a palatal injection may not be necessary when articaine is delivered in a buccal infiltration [46] [47] [48] and that most impacted maxillary third molar extractions with GENERAL control during endodontic procedures. 60 It may be difficult to achieve profound anaesthesia in mandibular posterior teeth, especially when the IANB technique is implemented. 61 Articaine has not been shown to be superior to lignocaine or mepivacaine in achieving adequate pain control during endodontic treatment in mandibular posterior teeth with IP when the IANB is administered [62] [63] [64] or when the Gow-Gates Block (GGB) is administered. 59 When articaine was compared in several techniques for mandibular anaesthesia for endodontic treatment of teeth with IP, the GGB technique had a significantly higher success rate than the IANB, VaziraniAkinosi Block (VAB) and buccal plus lingual infiltrations, 65 however, no technique or anaesthetic provided any acceptable pain control. 62, 63, 65 These results differ to a study which compared IANB, GGB and VAB with lignocaine in sound mandibular teeth showing no significant difference in efficacy between the three methods. 66 After a lignocaine IANB, no significant difference in pain control was found between articaine and lignocaine for a supplemental buccal infiltration. 58 Following a lignocaine IANB and long buccal nerve block (LB) that did not achieve profound anaesthesia in a mandibular posterior tooth during endodontic treatment, a prospective study with no experimental variable found that a supplemental articaine buccal infiltration had a 58% success rate but did not provide adequate or predictable pulpal anaesthesia. 67 When buccal and lingual infiltrations supplemental to a lignocaine IANB were compared on mandibular teeth with IP, articaine had a significantly higher articaine can be performed without palatal anaesthesia. 21 These results corroborate findings by Badcock et al. 49 who compared lignocaine and placebo saline palatal infiltrations in the extraction of maxillary third molars and concluded that when lignocaine is used in a buccal infiltration, a palatal injection of local anaesthetic may not be required. However, a clinical and magnetic resonance imaging study evaluating palatal diffusion of articaine in the maxillary first premolar and molar region did not detect the presence of anaesthesia following needle prick stimulation or articaine in the palatal tissues after buccal infiltration. 50 The current literature reports conflicting results regarding the clinical advantage articaine may have over other LAs. A meta-analysis comparing articaine and lignocaine concluded that articaine is more likely to achieve anaesthetic success than lignocaine in the first molar region. 51 However, this meta-analysis did not take into account the effect of local inflammation or variability of anaesthetic success with certain LA administration techniques such as the IANB. In summary, there is insufficient evidence indicating articaine's superiority and many studies show that its properties are similar to that of other available local anaesthetics (Table 1) .
LOCAL ANAESTHETIC FAILURE
Many mechanisms for local anaesthetic failure have been discussed elsewhere; [52] [53] [54] [55] it is believed that articaine may provide anaesthetic success when other LAs are unable to provide profound anaesthesia. 2 Teeth with irreversible pulpitis (IP) are perceived to be more difficult to anaesthetise than those with normal pulps because nerves arising from inflamed tissue have altered resting potentials and decreased excitability thresholds. 56, 57 Studies comparing anaesthetic success of different LAs in teeth with IP have defined success as patients reporting no to mild pain on a Visual Analogue Scale (VAS) pain scale during the endodontic procedure. When used as a supplemental anaesthetic, after lignocaine did not provide profound anaesthesia during endodontic treatment in maxillary teeth, no difference in pain experience was found between articaine and lignocaine. 58, 59 Alternatively, articaine was shown to be superior to lignocaine in maxillary posterior teeth for pain 68 No significant difference was found between IANB and buccal infiltration and IANB and PDL injection with articaine in the mandibular first molar; both having high success rates. 69 The articaine IANB and PDL injection success rate (83%) was higher than lignocaine (56%) when used in a similar setting. 70 Articaine in an intraosseous injection (IO) supplemental to IANB and LB in mandibular posterior teeth with IP had a success rate of 86% when delivered with the Stabident system (Fairfax Dental Inc., Miami, FL, USA), 71 which were comparable to success rates of lignocaine Stabident injections supplemental to IANB in mandibular posterior teeth with IP of 90 and 91% 72, 73 and with lignocaine X-tip (X-tip Technologies, Lakewood, NJ, USA) IO injections of 82%. 74 In general, the evidence indicates little benefit in using articaine for IP (Table 2) .
USE IN CHILDREN
In 3-12-year-old children, serum concentrations of articaine were comparable to those in adults, with maximum concentrations of a 2% solution significantly lower than that of a 4% one. 75 Common adverse articaine reactions in children have been reported to be numbness and soft tissue injuries, with prolonged numbness being the most common, mainly occurring in children younger than seven. 76 Whilst the manufacturer does not recommend articaine use in children younger than four years of age, 77 an early retrospective report on 211 children under four years of age gave initial evidence reporting no adverse systemic reactions. 78 An American survey 79 reported that 21% of 373 dentists surveyed had used articaine in the 2-3-year-old group. In mandibular primary molars and canines undergoing operative dentistry, a buccal infiltration of articaine achieved anaesthetic success for all procedures in a study of 50 children aged 4-12 years. 80 In children 3-6 years of age, no difference in the effectiveness of mandibular infiltration was found between articaine, mepivacaine and prilocaine. 81 Lignocaine infiltrations in primary molars were effective and reliable for amalgam and stainless steel crown restorations but not for a pulpotomy. 82 Articaine has been as effective as lignocaine when used in patients aged 4-12 83 and 5-13. 84 Articaine IO injections in 4-16-year-old children were able to provide successful anaesthesia for a high proportion of deciduous and permanent teeth, with a significantly higher success rate in maxillary teeth. 85 The available literature on articaine use in children shows that it is safe and effective for clinical procedures in children of all ages.
SAFETY
All local anaesthetics have the potential to be unsafe, with adverse effects including symptoms of dizziness, disorientation, tremors, convulsions, seizures, hypotension and cardiac and respiratory depression. 6, 86, 87 Articaine is one of the safer local anaesthetics due to its rapid metabolism into an inactive metabolite, decreasing the risk of systemic toxicity and overdose, even after repeated injection. 6 Early studies on articaine reported no toxic reactions from 100 injections, 23 in 211 paediatric patients 81 and a recent study showed a low number of adverse events comparable to that of lignocaine. 3 Other adverse reactions to articaine have been reported, including hypersensitivity, 88 ophthalmologic complications, [89] [90] [91] [92] ischaemic skin necrosis 93 and fever, chills and arthralgia. 94 Controversy exists regarding articaine safety following non-surgical dental procedures with an IANB, which suggests articaine having a higher incidence of paraesthesia (persistent anaesthesia or an abnormal or unprovoked sensation). These suggestions have been based on data from four retrospective reports [95] [96] [97] [98] and two abstracts. 99, 100 When complete data were available, articaine was the LA most commonly associated with paraesthesia (34-60%), [95] [96] [97] [98] the majority of cases involved the lingual nerve (71-93%) [95] [96] [97] [98] and no nerves in the maxilla were affected. Similar studies before articaine release in the USA also showed the lingual nerve had a similar incidence of involvement (71-83%) with lignocaine being the most commonly used agent (67%). 101, 102 A later study using data when articaine was widely available in the USA contradicted early results, with lignocaine being the most common LA (35%), followed by articaine and prilocaine (30% each). 103 However, the most recent retrospective study 98 on voluntary reporting of adverse reactions following LA administration in the USA showed that from the available data, 4% solutions of articaine and prilocaine were associated with a higher frequency of paraesthesia than LAs of a lower concentration. Of all reports, only one case 101 was associated with a GGB 104 and the remaining with an IANB -the Halstead technique. All reports documenting paraesthesia after IANB only included non surgical procedures 95, 97, [99] [100] [101] [102] [103] except for one 96 which included 'one simple dental extraction' and another 98 in which 64% of their sample consisted of assumed non-surgical paraesthesia cases as the procedural details were unknown. The methodology of data recruitment needs to be carefully examined. All reports suggestive of articaine having neurotoxic potential [95] [96] [97] [98] [99] [100] involved voluntary reporting or referral to the respective insurance board for paraesthesia assessment. As referral following paraesthesia was not compulsory, the collected data cannot be considered a representative sample. This has the potential for underreporting, which 'almost certainly exists' 97 and can change the distribution and incidence of nerves affected and LA agents used. The reasons for reporting or not reporting an adverse outcome is beyond the scope of this paper and is an area that needs further research in order to reduce reporting bias. In addition, some studies did not include complete data and instead made assumptions on the procedures involved. Paraesthesia following non-surgical dental procedures is uncommon and the mechanism of nerve damage is unknown, 101 however, proposed theories regarding susceptibility of the lingual nerve to damage include: direct needle trauma, intraneural haematoma formation, local anaesthetic toxicity and the fascicular pattern. 101, 105 Incidences of lingual nerve damage caused by mandibular block anaesthesia for non-surgical dental procedures have been reported to be between 0.15% 106 and 0.54% 107 and gross estimations of the incidence of paraesthesia after IANB administration for non surgical procedures range from 1:26,762 to 1:785,000, with the assumption that half of all LA injections involve IANB injections. 95: 97, 101: 102 To date, there is only one report in the literature of maxillary paraesthesia involving articaine, however, it was following an extraction. 108 Only one report of maxillary non-surgical paraesthesia has been documented, following GENERAL outcomes. This study compared 4% A100 and 2% L100 for simple and complex dental procedures, with respective sample sizes of 882 and 443 and respective incidences of paraesthesia of 1 and less than 1%, and did not offer any suggestion of articaine being associated with an increased risk of paraesthesia. In light of this evidence, along with efficacy studies comparing IANBs of articaine with other LAs in sound teeth 37 and teeth with IP, [62] [63] [64] the literature shows that there is neither no significant clinical advantage nor significant risk of developing a paraesthesia when using articaine instead of lignocaine for an IANB. Therefore, from the current available literature, there is no scientific evidence demonstrating that articaine as a 4% solution is neurotoxic or unsafe to use in any aspect of clinical dentistry.
CONCLUSIONS
Although there may be controversy regarding its safety and advantages in comparison to other local anaesthetics, there is no conclusive evidence demonstrating neurotoxicity or significantly superior anaesthetic properties of articaine for dental procedures. Articaine is a safe and effective local anaesthetic drug to use in all aspects of clinical dentistry for patients of all ages, with properties comparable to other common local anaesthetic agents. Therefore, at this time, the decision to use articaine cannot be based on any convincing evidence of superiority over other LA drugs, rather the choice will be based on the personal preference and experiences of individual clinicians.
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palatal-anterior superior alveolar nerve block with lignocaine and mepivacaine. 109 From the available literature, it is evident that paraesthesia is an extremely rare occurrence and regardless of the LA used, the majority of non surgical paraesthesia cases affect the lingual nerve after IANB administration. Currently no scientific proof exists for this observation. Other reports have suggested that it is not the anaesthetic agent itself but instead the available concentration. 97, 98, 110 This is due to 4% articaine and prilocaine preparations being reported with increased incidences of paraesthesia, but these claims are unproven. Whilst there may be in vitro animal studies linking increased anaesthetic concentration and neurotoxicity, 111 it does not explain why the majority of non-surgical paraesthesias after IANB preferentially involve the lingual nerve. No scientific evidence exists supporting the claim that articaine is associated with increased paraesthesia 112, 113 and a clear causal relationship has not been established in the literature between anaesthetic agent and neurological complications, such as paraesthesia. 114 These statements currently remain true. All studies suggesting articaine having an increased risk of neurotoxicity are retrospective and biased in data recruitment, are not high levels of evidence and hence are not suitable for strong recommendations. 115 In order to prove claims of increased paraesthesia, the current incidence of paraesthesia associated with other anaesthetics needs to be clearly established and further studies are needed to determine a significant increase in paraesthesia associated with articaine, if any. These reports would need to be randomised controlled trials (RCTs) as they not only will contribute to the highest level of evidence, but their design can maximise control over the environment providing the most convincing causal relationship. 116 Gaffen and Haas concede that 'it would take an unrealistically large trial or cohort to detect statistically significant differences for an event as rare as nonsurgical paraesthesia' and, in reference to the current data on RCTs using articaine, advocate that 'no conclusions regarding permanent paraesthesia should be made from these particular studies'. 97 To date there is only one RCT 3 comparing articaine with other LAs reporting adverse
